Efficacy of risk-reducing salpingo-oophorectomy in BRCA1-2 variants and clinical outcomes of follow-up in patients with isolated serous tubal intraepithelial carcinoma (STIC)

被引:13
|
作者
Saccardi, Carlo [1 ]
Zovato, Stefania [2 ]
Spagnol, Giulia [1 ]
Bonaldo, Giulio [1 ]
Marchetti, Matteo [1 ]
Alessandrini, Lara [3 ]
Tognazzo, Silvia [2 ]
Guerriero, Angela [3 ]
Vitagliano, Amerigo [1 ]
Lagana, Antonio Simone [4 ]
Noventa, Marco [1 ]
机构
[1] Univ Padua, Dept Women & Childrens Hlth, Clin Gynaecol & Obstet, Via Giustiniani 3, I-3100 Padua, Italy
[2] IOV IRCCS, Veneto Inst Oncol, Familial Canc Clin & Oncoendocrinol, Padua, Italy
[3] Univ Padua, Dept Med DIMED, Surg Pathol & Cytopathol Unit, Padua, Italy
[4] Univ Insubria, Filippo Del Ponte Hosp, Dept Obstet & Gynaecol, Varese, Italy
关键词
BRCA mutation; Risk-reducing salpingo-oophorectomy; Serous tubal intraepithelial carcinoma; Occult cancer; Primary peritoneal carcinoma; Peritoneal carcinoma; MUTATION CARRIERS; FALLOPIAN-TUBE; PROPHYLACTIC OOPHORECTOMY; BREAST-CANCER; OVARIAN; WOMEN; COHORT; OCCULT;
D O I
10.1016/j.ygyno.2021.08.021
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective. Serous tubal intraepithelial carcinoma (STIC) is currently considered the precursor lesion of pelvic high-grade serous carcinoma. The management of STIC diagnosed after risk-reducing salpingo-oophorectomy (RRSO) in women with BRCA1-2 variants remains unclear. The aim of our study was to evaluate the incidence of STIC, serous tubal intraepithelial lesions (STIL) and occult invasive cancer (OC) and to determine the longterm outcomes of these patients. Methods. We conducted a retrospective study of patients with BRCA 1-2 variants who underwent RRSO between January-2010 and Dicember-2020 at the Clinic of Gynaecology of University of Padova. Inclusion criteria: women with a negative pelvic examination at the last screening prior to RRSO, patients with fallopian tubes analysed using the SEE-FIM protocol. Exclusion criteria: patients with a positive gynaecologic screening or with ovarian/tubal cancer prior to RRSO. Results. We included 153 patients. STICs were diagnosed in 4 patients (2.6%) and STILs in 6 patients (3.9%). None of the patients with STIC underwent restaging surgery or adjuvant chemotherapy; all patients were followed closely every 6 months. None of the patients developed primary peritoneal carcinomas (PPCs) with a median FUP of 54.5 months (15-106). OC was diagnosed in 3 patients (2%). All patients with OC underwent staging surgery, and one patient developed a peritoneal carcinoma (PC) after 18 months by staging surgery. Conclusion(s). The incidence of STIC, STIL and OC after RRSO in BRCA1-2 variants was low. Our results demonstrated that long-term close surveillance in patients diagnosed with STIC should be considered a possible management strategy. (c) 2021 Elsevier Inc. All rights reserved.
引用
收藏
页码:364 / 370
页数:7
相关论文
共 50 条
  • [21] Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers
    Mavaddat, Nasim
    Antoniou, Antonis C.
    Mooij, Thea M.
    Hooning, Maartje J.
    Heemskerk-Gerritsen, Bernadette A.
    Nogues, Catherine
    Laborde, Lilian
    Breysse, Emmanuel
    Stoppa-Lyonnet, Dominique
    Gauthier-Villars, Marion
    Buecher, Bruno
    Caron, Olivier
    Fourme-Mouret, Emmanuelle
    Fricker, Jean-Pierre
    Lasset, Christine
    Bonadona, Valerie
    Berthet, Pascaline
    Faivre, Laurence
    Luporsi, Elisabeth
    Mari, Veronique
    Gladieff, Laurence
    Gesta, Paul
    Sobol, Hagay
    Eisinger, Francois
    Nogues, Catherine
    Longy, Michel
    Dugast, Catherine
    Colas, Chrystelle
    Coupier, Isabelle
    Pujol, Pascal
    Corsini, Carole
    Lortholary, Alain
    Vennin, Philippe
    Adenis, Claude
    Nguyen, Tan Dat
    Delnatte, Capucine
    Tinat, Julie
    Tennevet, Isabelle
    Limacher, Jean-Marc
    Maugard, Christine
    Bignon, Yves-Jean
    Demange, Liliane
    Penet, Clotilde
    Dreyfus, Helene
    Cohen-Haguenauer, Odile
    Venat-Bouvet, Laurence
    Leroux, Dominique
    Zattara-Cannoni, Helene
    Fert-Ferrer, Sandra
    Bera, Odile
    BREAST CANCER RESEARCH, 2020, 22 (01)
  • [22] Risk-reducing salpingo-oophorectomy and breast cancer risk in BRCA1 or BRCA2 mutation carriers: A systematic review and meta-analysis
    Wang, Yizi
    Song, Zixuan
    Zhang, Shitai
    Wang, Xiaoying
    Li, Peiwen
    EJSO, 2022, 48 (06): : 1209 - 1216
  • [23] Long term follow up of BRCA1 and BRCA2 mutation carriers with unsuspected neoplasia identified at risk reducing salpingo-oophorectomy
    Powell, C. B.
    Swisher, E. M.
    Cass, I.
    McLennan, J.
    Norquist, B.
    Garcia, R. L.
    Lester, J.
    Karlan, B. Y.
    Chen, L.
    GYNECOLOGIC ONCOLOGY, 2013, 129 (02) : 364 - 371
  • [24] Breast Cancer Incidence After Risk-Reducing Salpingo-Oophorectomy in BRCA1 and BRCA2 Mutation Carriers
    Fakkert, Ingrid E.
    Mourits, Marian J. E.
    Jansen, Liesbeth
    van der Kolk, Dorina M.
    Meijer, Kees
    Oosterwijk, Jan C.
    van der Vegt, Bert
    Greuter, Marcel J. W.
    de Bock, Geertruida H.
    CANCER PREVENTION RESEARCH, 2012, 5 (11) : 1291 - 1297
  • [25] Retrospective evaluation of risk-reducing salpingo-oophorectomy for BRCA1/2 pathogenic variant carriers among a cohort study in a single institution
    Kobayashi, Yusuke
    Hirasawa, Akira
    Chiyoda, Tatsuyuki
    Ueki, Arisa
    Masuda, Kenta
    Misu, Kumiko
    Kawaida, Miho
    Hayashi, Shigenori
    Kataoka, Fumio
    Banno, Kouji
    Kosaki, Kenjiro
    Aoki, Daisuke
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2021, 51 (02) : 213 - 217
  • [26] Use of total abdominal hysterectomy and hormone replacement therapy in BRCA1 and BRCA2 mutation carriers undergoing risk-reducing salpingo-oophorectomy
    Gabriel, C. A.
    Tigges-Cardwell, J.
    Stopfer, J.
    Erlichman, J.
    Nathanson, K.
    Domchek, S. M.
    FAMILIAL CANCER, 2009, 8 (01) : 23 - 28
  • [27] Subsequent breast and high grade serous carcinomas after risk-reducing salpingo-oophorectomy in BRCA mutation carriers and patients with history of breast cancer
    Straub, Melissa M.
    Podoll, Mirna B.
    David, Stephanie N.
    Wiesner, Georgia L.
    Desouki, Mohamed M.
    ANNALS OF DIAGNOSTIC PATHOLOGY, 2018, 36 : 28 - 30
  • [28] Non-cancer endpoints in BRCA1/2 carriers after risk-reducing salpingo-oophorectomy
    J. V. Cohen
    L. Chiel
    L. Boghossian
    M. Jones
    J. E. Stopfer
    J. Powers
    T. R. Rebbeck
    K. L. Nathanson
    S. M. Domchek
    Familial Cancer, 2012, 11 : 69 - 75
  • [29] Meta-analysis of Risk Reduction Estimates Associated With Risk-Reducing Salpingo-oophorectomy in BRCA1 or BRCA2 Mutation Carriers
    Rebbeck, Timothy R.
    Kauff, Noah D.
    Domchek, Susan M.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2009, 101 (02): : 80 - 87
  • [30] Pathological findings and long-term prognosis in Korean BRCA1/2 mutation carriers undergoing risk-reducing salpingo-oophorectomy
    Kang, Ok-Ju
    Lee, Shin-Wha
    Kim, Ju-Hyun
    Park, Jeong-Yeol
    Suh, Dae-Shik
    Kim, Dae-Yeon
    Kim, Jong-Hyeok
    Kim, Yong-Man
    Kim, Young-Tak
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2023, 33 (11) : 1743 - 1749